Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: D11

Adtralza

Dermatitis, Atopic

Marketing Authorisation Holder: LEO Pharma A/S

EMA Authorisation: 17/06/2021

INN: tralokinumab

Indication

Adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Adtralza — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.